ESR1 and breast cancer: Further significance of this signaling pathway in cancer is highlighted by patient data which show that the combination of changes in NOX2/TRPM8 expression in estrogen receptor-negative (ER−) breast cancer patients is correlated with poor overall survival (hazard ratio, 2.4).